Pharmacotherapy of insomnia

Expert Opinion on Pharmacotherapy
Octavian C Ioachimescu, Ali A El-Solh

Abstract

Insomnia is one of the most prevalent sleep disorders in developed countries, being surpassed only by chronic sleep deprivation. Patients with insomnia tend to have an altered quality of life, impaired daytime functioning and an increased risk of work accidents and motor vehicle crashes. Insomnia is commonly associated with chronic medical conditions, metabolic illnesses and mental disorders (such as depression and anxiety), with which there is a dual, reciprocal relationship. This paper focuses on current pharmacotherapy options for the treatment of insomnia, particularly benzodiazepine receptor agonists, which nowadays represent the mainstay of hypnotic therapy. The melatonin receptor antagonist, ramelteon, is reviewed (an alternative for some patients with only sleep-onset difficulty), as are sedating antidepressants, which are commonly used 'off-label' to treat insomnia, despite limited efficacy data and potential significant safety concerns. Orexin (OX) antagonists are also discussed, especially those that block OX2 or both OX1 and OX2 receptors, as these are the most promising new agents for the treatment of insomnia, with encouraging results in preliminary clinical trials. Research to evaluate and formulate treatments fo...Continue Reading

References

Dec 15, 1989·JAMA : the Journal of the American Medical Association·W A RayW Downey
Sep 17, 1987·The New England Journal of Medicine·D J GreenblattR I Shader
Feb 1, 1988·The Journal of Urology·C C Carson, R D Mino
Aug 1, 1983·British Journal of Clinical Pharmacology·I MontgomeryK Adam
Jan 1, 1995·Journal of General Internal Medicine·M KuppermannS K Fifer
Jan 1, 1994·European Archives of Psychiatry and Clinical Neuroscience·F HohagenM Berger
Jul 16, 1994·BMJ : British Medical Journal·I HaimovP Lavie
Apr 1, 1994·Journal of Clinical Psychopharmacology·W B Mendelson
Jan 1, 1993·Annual Review of Pharmacology and Toxicology·N G Bowery
Sep 1, 1995·Sleep·I HaimovN Zisapel
Sep 1, 1996·Psychopharmacology·T RoehrsT Roth
Apr 1, 1997·Clinical Neuropharmacology·J C WareG W Vogel
Nov 28, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M M OhayonC Guilleminault
Jan 7, 1998·JAMA : the Journal of the American Medical Association·P D NowellD J Kupfer
Oct 10, 1998·Psychiatry and Clinical Neurosciences·H YamaderaS Endo
Oct 17, 1998·Psychosomatic Medicine·M H Bonnet, D L Arand
Mar 13, 1999·The Journal of Biological Chemistry·G Y NgG P O'Neill
Mar 23, 1999·JAMA : the Journal of the American Medical Association·C M MorinD Brink
Jul 8, 1999·Biological Psychiatry·R J Salin-PascualM R Laurrabaquio
Aug 10, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·D J GreenblattR I Shader
Oct 12, 2000·The New England Journal of Medicine·R L SackA J Lewy
Nov 22, 2000·Molecular and Cellular Neurosciences·A CouveM N Pangalos
Mar 10, 2001·Trends in Pharmacological Sciences·D ZhangS A Lipton
Dec 26, 2001·The Journal of Pharmacology and Experimental Therapeutics·H MöhlerU Rudolph
Jan 5, 2002·The American Journal of Psychiatry·Michael T SmithDaniel J Buysse
May 15, 2002·Journal of Clinical Psychopharmacology·Sabrina PaternitiAnnick Alpérovitch
Jul 20, 2002·Journal of Psychosomatic Research·R H Y LiS Y Y Fong
Sep 17, 2002·European Journal of Pharmacology·Enrico SannaGiovanni Biggio
Sep 28, 2002·Journal of Clinical Psychopharmacology·Gary S RichardsonThomas Roth
Jan 18, 2003·Sleep Medicine Reviews·Maurice M Ohayon
Feb 5, 2003·Neuropsychobiology·Michel SchittecatteJean Wilmotte
Jul 31, 2003·Life Sciences·David R Burt
Aug 21, 2003·Sleep Medicine Reviews·Edward J Stepanski, James K Wyatt
Sep 6, 2003·Age and Ageing·Karen D KellyKaven D Kelly
Oct 2, 2003·The Annals of Pharmacotherapy·S Pirzada SattarFrederick Petty
Nov 1, 2003·Sleep Medicine·Timothy I Morgenthaler, Michael H Silber

❮ Previous
Next ❯

Citations

Apr 8, 2015·Chest·Jessica C LevensonDaniel J Buysse
Feb 13, 2013·Continuum : Lifelong Learning in Neurology·David N Neubauer
May 28, 2013·Current Opinion in Neurobiology·Jason Rihel, Alexander F Schier
Dec 3, 2014·Clinical Therapeutics·James MacFarlaneJacques Montplaisir
May 26, 2016·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Qun WangXiaomei Li
Aug 5, 2017·Continuum : Lifelong Learning in Neurology·Alon Y Avidan, David N Neubauer
Oct 10, 2014·The Cancer Journal·Mellar P Davis, Harold W Goforth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Developmental Neurobiology
Jason Rihel, Alexander F Schier
Pflügers Archiv : European journal of physiology
Jeffrey M Ellenbogen, Edward F Pace-Schott
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Carolien van RijnsoeverFlorence Crestani
© 2021 Meta ULC. All rights reserved